Rituximab, B-lymphocyte depletion, and beta-cell function

Journal article

Peer reviewed

Seiho Nagafuchi, Hitoshi Katsuta and Keizo Anzai

The New England journal of medicine, Vol.362(8), pp.761; author reply 761-761

2010-02-25

PMID: 20181981

Abstract

Antibodies, Monoclonal, Murine-Derived

Antibodies, Monoclonal - pharmacology

Humans

Antibodies, Monoclonal - adverse effects

Rituximab

Antibodies, Monoclonal - therapeutic use

Diabetes Mellitus, Type 1 - drug therapy

B-Lymphocytes - drug effects

Insulin-Secreting Cells - drug effects

T-Lymphocytes - immunology

Immunologic Factors - adverse effects

Diabetes Mellitus, Type 1 - immunology

Immunologic Factors - pharmacology

Immunologic Factors - therapeutic use

4 Record Views

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.26 Diabetes; 1.26.1016 Type 1 Diabetes
Web Of Science research areas: Immunology
ESI research areas: Clinical Medicine

This output has contributed to the advancement of the following goals:

Source: InCites

Title: Rituximab, B-lymphocyte depletion, and beta-cell function
Creators: Seiho Nagafuchi
Hitoshi Katsuta
Keizo Anzai
Publication Details: The New England journal of medicine, Vol.362(8), pp.761; author reply 761-761
Publisher: United States
Language: English
Resource Type: Journal article
PMID: 20181981
Record Identifier: 991031561115002976